Reprieve Cardiovascular is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
02/20/24	$42,000,000	Series A	Arboretum Ventures Deerfield Management Company, L.P. Genesis Capital Lightstone Ventures Sante Ventures	undisclosed